Jump to content

Brelgometon

From Wikipedia, the free encyclopedia

Brelgometon
Clinical data
Other namesATH-1105; ATH1105
Drug classHepatocyte growth factor (HGF)–c-MET signaling positive modulator; Neuroprotective agent; Anti-inflammatory drug
Identifiers
  • (6S)-6-methyl-8-[(2S)-2-methylbutyl]-1-[[4-(trifluoromethyl)phenyl]methyl]-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-4,7-dione
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC21H28F3N3O2
Molar mass411.469 g·mol−1
3D model (JSmol)
  • CC[C@H](C)CN1CC2N(CCC(=O)N2[C@H](C1=O)C)CC3=CC=C(C=C3)C(F)(F)F
  • InChI=1S/C21H28F3N3O2/c1-4-14(2)11-26-13-18-25(10-9-19(28)27(18)15(3)20(26)29)12-16-5-7-17(8-6-16)21(22,23)24/h5-8,14-15,18H,4,9-13H2,1-3H3/t14-,15-,18?/m0/s1
  • Key:DWLDFDZUDSQLPP-INHRHCAVSA-N

Brelgometon (INNTooltip International Nonproprietary Name; developmental code name ATH-1105) is a positive modulator of hepatocyte growth factor (HGF)–c-MET signaling which is under development for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).[1][2][3][4] It is a small-molecule and has favorable drug-like properties, such as oral bioavailability and blood–brain barrier permeabiliy.[3][4] The drug shows potent neuroprotective and anti-inflammatory effects in preclinical research, including in models of ALS.[3][4] It was originated by Athira Pharma and is under development by LeonaBio.[1][2] As of April 2026, the drug is in phase 1 clinical trials for ALS and is in the preclinical research stage of development for FTD.[1][2] A phase 2 trial for ALS is being planned for the second half of 2026.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 "Brelgometon - LeonaBio". adisinsight.springer.com. Retrieved 27 October 2026.
  2. 1 2 3 "Delving into the Latest Updates on ATH-1105 with Synapse". Synapse. 24 October 2026. Retrieved 27 October 2026.
  3. 1 2 3 Berthiaume AA, Reda SM, Kleist KN, Setti SE, Wu W, Johnston JL, et al. (2024). "ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS". Frontiers in Neuroscience. 18 1348157. doi:10.3389/fnins.2024.1348157. PMC 10881713. PMID 38389786.
  4. 1 2 3 Berthiaume AA, Kleist KN, Reda SM, Setti SE, Wu W, Johnston JL, et al. (2025). "ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole". Frontiers in Neurology. 16 1582765. doi:10.3389/fneur.2025.1582765. PMC 12825224. PMID 41586107.